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Tuberculosis (TB) and HIV are inextricably linked; 
not only are HIV-infected people up to 30 times more 
likely to develop active TB in their lifetimes, but they 
also have a higher risk of dying from TB than those 
who are not infected with HIV.[1-3] This dual-disease 
phenomenon has significant implications for South Africa (SA), 
which has the highest number of TB/HIV co-infected patients in the 
world.[1-3]
Anti-TB drug-induced liver injury (TB DILI) is one of the most 
serious adverse consequences of TB treatment (TBT), with a significant 
impact on TBT outcomes. A proportion of patients who experience TB 
DILI will require modification of the highly effective standard regimen, 
which relegates them to suboptimal regimens and exposes them to 
poor treatment outcomes with increased morbidity and mortality.[4-6] 
Furthermore, TB DILI impacts negatively on health resources as it 
increases costs and utilisation of health services.[7] Examples of this include 
increased nurse and physician visits, and the more intensive testing and 
monitoring that become necessary. The consequences of TB DILI are 
experienced most prominently by the developing world, including SA, 
where resources are limited and the TB disease burden is high.
The effect of antiretroviral therapy (ART) on TB DILI is not clear. 
A study conducted in both hospitalised patients and outpatients in 
Jimma, Ethiopia, found that the effect of ART is not significantly 
associated with outcome or adverse effects in TB/HIV co-infected 
patients.[8] However, a study conducted in hospitalised patients in 
Cape Town, SA, demonstrated a higher in-hospital and 3-month 
mortality of 35% in the ART/TB DILI group compared with 27% in 
patients with TB DILI alone. This was significantly higher than the 
8% mortality at 6 months among the general population of patients 
with TB/HIV co-infection treated at the hospital.[9]
The aim of this article is to describe patient characteristics of 
an SA adult HIV-infected population presenting with TB DILI, 
determine the factors that impact on the reintroduction of a standard 
or modified TBT regimen, and compare TB DILI with ART/TB DILI.
Methods
Study site and population
This study was a retrospective folder review of adult HIV-infected 
TB DILI patients presenting to a hospital-based TB clinic in 
Johannesburg, SA, between 1 July 2009 and 30 September 2012.
Included were all adult (age ≥18 years) HIV-infected TB DILI patients 
receiving standard first-line TBT for confirmed or probable active 
TB. Standard first-line TBT is a fixed-dose combination of rifampicin 
(RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (ETH) 
during the intensive phase of treatment, and RIF and INH during the 
continuation phase of treatment. The diagnosis of TB was considered 
confirmed when acid-fast bacilli could be demonstrated by microscopy, 
when Mycobacterium tuberculosis (MTB) was detected by a molecular 
amplification technique (Cepheid GeneXpert MTB/RIF, USA; Genotype 
MTBDR Hain Lifescience, GmbH, Germany), or when a tissue biopsy 
sample demonstrated histopathological changes in keeping with TB. 
In the absence of such confirmation, the diagnosis was considered 
probable when clinical and/or radiological signs of TB infection were 
associated with a definitive response to treatment after initiating TBT. 
Patients were excluded if they had resistance to RIF or INH on line-
probe assay or phenotypic drug susceptibility testing, if neither clinic nor 
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hospital medical files were available for review, 
or if they presented at the TB clinic outside the 
study period.
A diagnosis of TB DILI was defined as: (i) 
alanine aminotransferase (ALT) level more 
than three times the upper limit of normal 
(ULN), associated with symptoms of acute 
hepatic injury (abdominal pain, nausea, 
vomiting, anorexia or jaundice); (ii) ALT level 
more than five times the ULN in the absence 
of any symptoms; or (iii) total bilirubin (TBR) 
more than two times the ULN. The ULN 
for ALT and TBR as per the SA National 
Health Laboratory Service reference range 
was 40 IU/L and 21 IU/L, respectively.
Study procedure
Information obtained from the patients’ 
medical records included date of birth, 
gender, site of TB, basis of diagnosis, phase of 
treatment, symptoms, comorbid conditions, 
hepatotoxin ingestion (including prescription 
medication, traditional or herbal remedies, 
and alcohol), HIV status, CD4 count, ART 
details, serial liver function tests (LFTs), 
viral hepatitis studies, abdominal ultrasound 
findings and TB drug reintroduction details.
Pattern of liver injury was based on the 
predominant pattern of liver enzyme elevation. 
An LFT that demonstrated a predominant 
elevation of TBR (v. ALT) was considered 
cholestatic, primarily elevated ALT (v. TBR) 
was considered transaminitis, and non-
discernible cases were considered mixed.
Study definitions
The exposure was defined as HIV-infected 
patients on ART presenting with TB DILI 
(ART/TB DILI) v. not on ART (TB DILI).
The main outcome of the study was the 
proportion of patients reintroduced to a 
standard or modified treatment regimen 
after a DILI diagnosis. A standard treatment 
regimen was defined as the successful 
reintroduction of a regimen containing RIF 
and INH, whereas a modified treatment 
regimen was defined as a case where 
worsening clinical or biochemical parameters 
precluded the reintroduction of both RIF 
and INH. Secondary outcomes included 
retention in care and rate of decline in LFT 
(TBR, ALT, gamma-glutamyl transferase, 
albumin) after TB DILI diagnosis. Loss to 
follow-up was defined as more than 180 days 
since the last clinic visit.
Statistical analysis
Patient demographics and clinical charac-
teristics of the cohort were summarised using 
descriptive statistics. Groups (TB DILI v. ART/
TB DILI) were compared using Student’s t-test 
for parametric or normally distributed data, 
the Kruskal-Wallis test for non-parametric 
data or data that are not normally distributed 
for continuous variables, and the χ2 test 
for proportions. The association between 
potential risk factors and reintroduction on 
a modified treatment regimen was performed 
using logistic regression to estimate the odds 
ratio (OR) with 95% confidence intervals 
(CIs). Data were collected and imported into 
SAS version 9.3 (SAS Institute Inc., USA) for 
analysis.
Ethics
The study was approved by the Human 
Research Ethics Committee of the University 
of the Witwatersrand, Johannesburg (Certi-
ficate number: M120750).
Results 
A total of 94 patients with TB DILI were 
identified from TB clinic records. Table 1 
shows the baseline characteristics of the study 







Age (years), median (IQR) 40 (33.7 - 44.9) 39 (32.9 - 44.7) 39 (34.5 - 44.7)
Gender male, n (%) 45 (47.9) 20 (48.8) 25 (47.2)
Site of TB, n (%)
Pulmonary 18 (19.1) 6 (14.6) 12 (22.6)
Extrapulmonary 76 (80.9) 35 (85.4) 41 (77.4)
CD4 (cells/µL), median (IQR) 77 (31 - 160) 79 (35 - 107) 76 (31 - 187)
<50, n (%) 38 (40.4) 16 (39.0) 22 (41.5)
51 - 100, n (%) 22 (23.4) 13 (31.7) 9 (17.0)
101 - 250, n (%) 24 (25.5) 10 (24.4) 14 (26.4)
>250, n (%) 10 (10.6) 2 (4.9) 8 (15.1)
Phase of TBT at DILI 
diagnosis, n (%)
Intensive phase 83 (88.3) 40 (97.6) 43 (81.1)
Continuation phase 8 (8.5) 1 (2.4) 7 (13.2)
Unknown 3 (3.2) 0 (0) 3 (5.7)
Symptomatic DILI, n (%) 59 (62.8) 21 (51.2) 38 (71.2)
Duration of TBT at DILI 
diagnosis (days), median (IQR)
31.0 (8.0 - 62.0) 11.0 (4.5 - 30.5) 53.0 (28.0 - 70.0)
Duration between stopping 
TBT and starting re-challenge 
(days), median (IQR)
2.0 (0.0 - 7.0) 1.0 (0.0 - 3.0) 5.0 (0.0 - 7.0)
Pattern of liver injury, n (%)
Cholestatic 39 (41.5) 17 (41.5) 22 (41.5)
Transaminitis 18 (19.1) 7 (17.0) 11 (20.8)
Mixed 37 (39.4) 17 (41.5) 20 (37.7)
Duration of ART at DILI 
diagnosis (days), median (IQR)
33.0 (20.0 - 81.0) 31.5 (25.0 - 62.0) 49.4 (27.5 - 245.5)




PI-containing regimen 4/53 (7.55)
Unknown 2/53 (3.77)
TBR (IU/L), median (IQR) 50.0 (24.0 - 89.0) 46.0 (14.5 - 93.5) 57.0 (26.0 - 84.0)
ALT (IU/L), median (IQR) 101.5 (58.0 - 202.0) 118.0 (74.5 - 241.0) 89 (55.0 - 202.0)
Albumin (g/L), median (IQR) 18.0 (15.0 - 22.0) 18.0 (15.0 - 21.5) 18.5 (16.0 - 24.0)
New treatment regimen, n (%)
Standard 56/78 (71.8) 29/35 (82.9) 27/43 (62.8)
Modified 22/78 (28.2) 6/35 (17.1) 16/43 (37.2)
NNRTI = non-nucleoside reverse-transcriptase inhibitors; NRTI = nucleoside reverse-transcriptase inhibitors; PI = protease inhibitor.
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population. The average patient age was 40 
years (interquartile range (IQR) 33.7 - 44.9). 
The study included 45 males (47.9%) and 
49 females (52.1%). Eighty-three cases of TB 
(88.3%) were considered to be confirmed 
diagnoses, and of these patients 80.9% had 
extrapulmonary TB. The median CD4 count at 
DILI diagnosis was 77 cells/µL (IQR 31 - 160).
In 83 cases (88.3%) patients presented with TB 
DILI while on the intensive phase of treatment. 
On average patients experienced symptoms for 
6.5 days (IQR 3.0 - 10.0) before seeking medical 
attention. However, only 59 patients (62.8%) 
had symptoms of TB DILI. The most common 
symptoms were jaundice, vomiting, abdominal 
pain and anorexia. Abdominal ultrasound was 
performed on 76 patients (80.8%), of whom the 
majority had one or more features suggesting 
abdominal TB. Patients had received TB 
treatment for an average of 31.0 days (IQR 8.0 - 
62.0) at the time of DILI diagnosis. The interval 
between stopping TBT and initiating a new 
treatment regimen was 2 days (IQR 0.0 - 7.0).
Exposure to various hepatotoxic drugs 
(excluding ART) and alcohol was found in 31 
(40.8%) and 13 (18.8%) cases, respectively. 
None of the patients was serologically 
positive for hepatitis A virus, whereas 9 
(12.3%) and 3 (4.1%) tested positive for 
hepatitis B surface antigen and anti-hepatitis 
C antibodies, respectively.
The pattern of liver injury most frequently 
encountered was cholestatic (41.5%), followed 
by mixed (39.4%) and transaminitis (19.1%).
In total, 53 patients (56.4%) were receiving 
ART, for a median duration of 33.3 days (IQR 
20 - 81) before the DILI diagnosis. The most 
common ART regimen was tenofovir (TDF), 
lamivudine (3TC) plus efavirenz (EFV) (69.8%). 
Patients with ART/TB DILI were similar to 
those with TB DILI in terms of age, gender, CD4 
count at DILI diagnosis, site of TB and pattern 
of liver injury. More patients with ART/TB 
DILI than TB DILI presented with symptomatic 
DILI (71.2% v. 51.2%; p=0.03). Patients with 
ART/TB DILI had a lower median ALT at 
DILI diagnosis, with a smaller proportion more 
than two times the ULN compared with those 
with TB DILI (89 IU/L v. 118 IU/L; p=0.008 
and 56.6% v. 73.2%; p=0.018). Furthermore, 
there was a significant difference between the 
groups for ALT decline between baseline and 
4 weeks (–76 U/L v. –23 IU/L; p=0.047), with 
greater changes observed in the TB DILI group. 
Patients with ART/TB DILI had been on TBT 
for longer than those with TB DILI (53 days v. 
11 days; p<0.001). The time between stopping 
TBT and reintroduction of new drugs was also 
longer in patients with ART/TB DILI (5.0 days 
v. 1.0 days; p=0.007). More patients with ART/
TB DILI than with TB DILI were reintroduced 
onto modified TBT (37.2% v. 17.1%; p=0.05, 
and crude OR 2.17; 95% CI 0.95 - 4.96).
Patients who were not reintroduced onto either 
standard or modified treatment regimens 
because they were lost from care (17.0%) were 
typically older (median age 41.3 years v. 38.9 
years), had lower CD4 counts (<50 cells/µL; 
50% v. 38.5%), had pulmonary TB (31.3% v. 
16.7%) and had symptomatic DILI (81.3% 
v. 59.0%), compared with those who were 
reintroduced. The rate of death/loss to follow-
up was higher (10/53; 18.9%) among those 
with ART/TB DILI than among those with TB 
DILI (6/41, 14.5%; p=0.588) (Table 2).
Overall, it took 17.0 days (IQR 14.0 - 72.0) 
from interrupting TBT to reaching a definitive 
treatment regimen (standard or modified). In 56 
patients (71.8%) a standard treatment regimen 
could be reintroduced, while 22 patients (28.2%) 
required a modified treatment regimen in order 
Table 2. Characteristics of patients who achieved standard or modified treatment 
regimen v. those who were lost from care
Characteristics





Gender male, n (%) 38 (48.7) 7 (43.8) 0.717
Age (years), median (IQR) 38.9 (33.7 - 44.6) 41.3 (38.8 - 51.9) 0.061
ALT at DILI diagnosis, median (IQR) 109 (59 - 218) 87 (57 - 132) 0.469
TBR at DILI diagnosis, median (IQR) 48 (21 - 92) 57 (39 - 81) 0.366
Symptomatic DILI, n (%) 46 (59.0) 13 (81.3) 0.105
CD4 count (cells/µL), median (IQR) 82 (31 - 162) 49 (27 - 152) 0.302
ART/TB DILI, n (%) 43/78 (55.1) 10/16 (62.5) 0.588
TB DILI, n (%) 35/78 (44.9) 6/16 (37.5)
DILI during intensive phase of TBT, n (%) 68 (87.2) 15 (93.8) 0.672
DILI after start of TBT (days), median (IQR) 32 (7 - 62) 29 (11 - 61) 0.992
Site of TB, n (%)
Pulmonary 13 (16.7) 5 (31.3) 0.178
Extrapulmonary 65 (83.3) 11 (68.8)
Concomitant medications, n (%) 24 (30.8) 6 (37.5) 0.727
Pattern of liver injury – mixed, n (%) 14 (18.0) 4 (25.0) 0.804









TB DILI 6/22 (27.3) 1 1
ART/TB DILI 16/22 (72.3) 2.17 (0.95 - 4.96) 1.52 (0.76 - 3.09)
Gender 
 Male 9/22 (40.9) 1 1
 Female 13/22 (59.1) 1.37 (0.66 - 2.83) 0.88 (0.52 - 1.51)
Age (years)
≤50 18/22 (81.8) 1 1
>50 4/22 (18.2) 1.94 (0.87 - 4.32) 1.65 (0.62 - 4.42)
Symptomatic DILI
No 6/22 (27.3) 1 1
Yes 16/22 (72.7) 1.57 (0.70 - 3.51) 1.03 (0.54 - 1.95)
CD4 count (cells/µL) 
 >100 9/22 (40.9) 1 1
<100 13/22 (59.1) 0.85 (0.42 - 1.75) 0.98 (0.57 - 1.69)
Site of TB 
Pulmonary 6/22 (27.3) 1 1
Extrapulmonary 16/22 (72.7) 0.53 (0.26 - 1.10) 0.77 (0.39 - 1.53)
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to continue TB therapy. We report the association between ART/TB DILI 
v. TB DILI (OR 1.52; 95% CI 0.76 - 3.09) with being reintroduced on a 
modified treatment regimen, adjusted by age, gender, symptomatic DILI, 
CD4 count at DILI diagnosis and site of TB. The ORs for symptomatic 
DILI and age >50 years were 1.03 (95% CI 0.54 - 1.95) and 1.65 (95% CI 
0.62 - 4.42), respectively, while female gender (0.88; 95% CI 0.52 - 1.51) and 
extrapulmonary TB (0.77; 95% CI 0.39 - 1.53) appeared protective (Table 3).
Patients reintroduced on a modified treatment regimen had a 
lower baseline median ALT (89.0 IU/L, IQR 55.0 - 202.0) than those 
introduced on a standard treatment regimen (118 IU/L, IQR 74.5 - 
241.0; p=0.030). The rate of decline of ALT and TBR 4 weeks after DILI 
diagnosis was slower in patients reintroduced on a modified treatment 
regimen (16.0% v. 46.0%; p=0.03) than in those reintroduced on a 
standard regimen (72.0% v. 63.0%; p=0.04).
Discussion
In this retrospective study we describe patient characteristics and 
final treatment regimen of 94 TB/HIV co-infected patients presenting 
with TB DILI at a hospital-based TB clinic. Previous studies have 
suggested that age >35 years, hypoalbuminaemia and female gender 
are risk factors for TB DILI.[10] This study suggests that age >35 years 
and hypoalbuminaemia are possible risk factors.
In 71.8% of TB DILI cases, a standard TBT regimen containing RIF 
and INH could be reintroduced. According to our study, higher ALT and 
shorter duration of symptoms at TB DILI diagnosis were associated with 
successful reintroduction of a standard TBT regimen. The association 
between higher ALT and successful reintroduction of a standard treatment 
regimen is unexpected; it may represent true hepatoxicity to PZA, which 
is reversible with drug cessation, or it may represent transient elevations 
of liver enzymes or unrelated liver injury as opposed to true TB DILI. 
Conversely, factors associated with a modified treatment regimen include 
ART, male gender, symptomatic DILI and age >50 years – although these 
did not achieve statistical significance.
In this study, more than half of the TB DILI patients were exposed to 
ART. Differentiating between TB DILI, ART-induced DILI and immune 
reconstitution inflammatory syndrome (IRIS) is challenging.[10-12] When 
comparing TB DILI patients on ART v. not on ART, we observed some 
interesting differences. Patients on ART tended to have a significantly 
longer duration of TBT at DILI diagnosis, lower ALT at DILI diagnosis, 
longer treatment interruption until rechallenge of TBT, smaller serial 
changes in ALT, and higher odds of receiving a modified TBT regimen. 
The differential diagnosis for these patients includes TB DILI, ART 
DILI, TB IRIS, viral hepatitis, other hepatotoxins, sepsis and chronic liver 
conditions. A definitive diagnosis for the deranged liver function is difficult 
to make because it requires a liver biopsy, which is not routinely performed. 
According to this study, healthcare workers seem to be more cautious with 
reintroducing TBT, especially PZA, in this ART patient group. Rechallenge 
with PZA was previously not recommended, but a recent trial has shown 
that most patients tolerate it.[13] Unfortunately we did not capture data on 
interruption or modification of ART. However, the majority of patients 
(69.8%) in this study were receiving a regimen (TDF/3TC/EFV) considered 
to pose low risk for the development of hepatotoxicity.[14]
Study limitations
The quality of data captured was dependent on information 
entered into the medical record. There were some instances where 
documentation was incomplete, most notably for exposure to other 
potentially hepatotoxic substances. A small sample size that reached 
the modified treatment regimen (n=22) may have limited our ability 
to estimate outcomes in this group accurately, so we interpret these 
results with caution and recommend a larger sample size and longer 
follow-up. We have limited data on LFTs before starting TBT, as these 
are not routinely done in SA. Furthermore, patients who died or were 
lost to follow-up were excluded from the analysis because they could 
not be reintroduced onto a standard or modified regimen. This may 
have introduced selection bias. However, there were no differences 
in the baseline characteristics of patients who died or defaulted as 
opposed to those who reached the study-defined endpoint (Table 2).
Conclusions
Owing to the lack of evidence to compare the efficacy of various 
reintroduction guidelines, the management of TB DILI remains a 
controversial topic that lacks a prevailing global consensus.[13] Most 
guidelines are based on expert opinion.[10-12] In 2013, the South African 
HIV Clinicians Society published a consensus statement on the 
management of TB DILI in HIV-infected individuals.[15] The consensus 
statement provides healthcare workers with practical guidance on 
reintroducing TBT and ART.
There is an important need for future studies to further investigate the 
underlying mechanism of TB DILI. The ability to differentiate true TB 
DILI from other hepatic insults will allow for more accurate diagnosis 
and appropriate management. IRIS, HIV-related opportunistic 
infections, and other hepatotoxins (e.g. alcohol and prescription and 
traditional medicines) are common in our setting and may masquerade 
as TB DILI. Patient education and counselling are simple yet important 
steps that can be taken to reduce the impact of TB DILI.
We have demonstrated that a significant proportion of patients will 
require modified TBT. These patients are likely to be males aged >50 
years who are on ART and present with symptomatic DILI. There 
also appears to be an association between ART and more severe DILI.
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